Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …

Background Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting cytotoxic
T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (…

Background There are limited data about the quality of immune-related adverse event (irAE)
reporting in immune checkpoint inhibitor (ICI) clinical trial publications. Methods A …

PURPOSE Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high
microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations …

Thrombosis and biofouling of extracorporeal circuits and indwelling medical devices cause
significant morbidity and mortality worldwide. We apply a bioinspired, omniphobic coating to …

PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with
previously treated, advanced microsatellite instability–high or mismatch repair–deficient (MSI-H/…

Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with cancer.
However, existing biomarkers do not reliably predict treatment response across diverse …

Purpose To establish the safety profile and antitumor activity of the anti–programmed death
1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic …

Background Patients with castration-resistant prostate cancer derive only modest clinical
benefit from available therapies. Blockade of the inhibitory programmed death 1 (PD-1) …

OBJECTIVE: To test the hypothesis that exposure to preeclampsia is associated with an
increased risk of bronchopulmonary dysplasia (BPD). STUDY DESIGN: A prospective cohort …